Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net (Tables)

Intangibles, net (Tables)

6 Months Ended

Jun. 30, 2022

Summary of aggregate consideration transferred in connection with VYNE Product Acquisition

The following table summarizes the aggregate consideration transferred for the assets acquired by Journey in connection with the VYNE Product Acquisition:



($ in thousands)	Aggregate Consideration Transferred
Consideration transferred to VYNE at closing	$	20,000
Fair value of deferred cash payment due January 2023		4,740
Transaction costs		223
Total consideration transferred at closing	$	24,963

Summary of assets acquired in VYNE Product Acquisition

The following table summarizes the assets acquired in the VYNE Product Acquisition:


($ in thousands)	Assets Recognized
Inventory	$	6,041
Identifiable intangibles:
Amzeeq		15,162
Zilxi		3,760
Fair value of net identifiable assets acquired	$	24,963

Schedule of JMC recognized expense related to its product licenses

The table below provides a summary of the Journey intangible assets as of June 30, 2022 and December 31, 2021, respectively:


	Estimated Useful
($ in thousands)	Lives (Years)	June 30, 2022		December 31, 2021

Intangible assets – product licenses	3 to 9	$	37,925	$	19,003
Accumulated amortization			(8,485)		(6,451)
Net intangible assets		$	29,440	$	12,552

Schedule of future amortization of intangible assets

The future amortization of these intangible assets is as follows:


	Total
($ in thousands)	Amortization
Six Months Ended December 31, 2022	$	2,033
December 31, 2023		4,067
December 31, 2024		4,068
December 31, 2025		4,067
December 31, 2026		2,855
Thereafter		8,408
Sub-total	$	25,498
Asset not yet placed in service:		3,942
Total	$	29,440